114P Nivolumab plus ipilimumab as first-line treatment for patients with advanced non-small cell lung cancer: A systematic review

Abstract

months (HR:0.40, p = 0.008). Subgroup analysis found that the PFS benefit of PC was evident in most subgroups excepting patients with brain metastasis. The 1-year overall survival rate of PC and PM were 89.0% and 78.3%, respectively. The ORR were 61.7% and 46.9% (p = 0.040), respectively. Conclusions: In patients with previously untreated, PD-L1≥50%, advanced NSCLC without EGFR or ALK mutations, the addition of pembrolizumab to standard platinum-based chemotherapy should be recommended as the preferred treatment.